Prostatic Neoplasms
447
40
72
240
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
87 trials with published results (19%)
Research Maturity
240 completed trials (54% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
13.2%
59 terminated out of 447 trials
80.3%
-6.3% vs benchmark
13%
57 trials in Phase 3/4
36%
87 of 240 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 240 completed trials
Clinical Trials (447)
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
Collection of Blood From Patients With Prostate Cancer
Evaluation of Atherosclerotic Plaques in Abdominal CT Studies
Hemodynamic Effects of Trendelenburg Position and Pneumoperitoneum in Urologic Robotic Surgery
Real-time Fluorescence Microscopy for Intraoperative Assessment of Prostate Biopsy Cores (FLASH)
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Cancer Oriented Understanding and Navigation Via Supportive and Educational Language Models (COUNSEL)
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)